Whole-exome sequencing of metastatic HER2 positive patients from the phase Ib Study of LZM005

This was an open-label, first-in-human phase I study. The study included phases Ia and Ib. In phase Ib, LZM005 was administered with trastuzumab and docetaxel at the MTD. The primary endpoints included safety, tolerability, and the dose for further studies. The secondary endpoints were PK, immunogenicity response, and biomarker analysis. Patients whose DCB persisted longer than 6 months were identified as good responders, while the counterparts were classified as poor responders.